Skip to content

Cannabis: all studies

Page 233 of 287: studies 2,321 to 2,330 of 2,868, newest first. Back to the cannabis overview

Research

Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer’s disease symptoms: a case report

Journal of Medical Case Reports July 17, 2022 Ana Carolina Ruver-Martins, Maíra Assunção Bicca, Fabiano Soares de Araujo et al.

Abstract Background Cannabinoid-based therapy has been shown to be promising and is emerging as crucial for the treatment of cognitive deficits, mental illnesses, and many diseases considered incurable. There is a need to find an appropriate therapy for Alzheimer’s disease, and cannabinoid-based therapy appears to be a feasible possibility. Case presentation This report addresses the beneficial...

DOI: 10.1186/s13256-022-03457-w (opens in new tab) Full text (opens in new tab) Microdosing Alzheimer’s disease Cannabinoids Cannabinoid extract +2

Magic Mushrooms – an exploratory look at how mental health professionals feel and think about Psilocybin

Psychiatry Research July 16, 2022 Thomas D Meyer, Priel Meir, Claudia Lex et al. 23 citations

Psilocybin recently received breakthrough status by the FDA for its use in treatment of depression. We therefore investigated mental health professionals' (MHPs) opinions on Psilocybin (n = 155). Overall, attitudes were neutral but self-rated knowledge of Psilocybin was low. The term used in the survey, 'Psilocybin' or 'Magic Mushrooms', did not significantly affect their responses. Some...

DOI: 10.1016/j.psychres.2022.114727 (opens in new tab) Psilocybin Hallucinogen Mental health Exploratory research +2

Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey.

British Journal of Pain July 14, 2022 Valerie Bonnelle, Will J Smith, Natasha L. Mason et al. 26 citations

Although several studies and reports have shown the potential analgesic use of serotonergic psychedelics in cancer pain, phantom limb pain and cluster headache, evidence supporting their use for chronic pain is still limited. The past years have seen a considerable renewal of interest toward the therapeutic use of these compounds for mood disorders, resulting in a marked increase in the number...

DOI: 10.1177/20494637221114962 (opens in new tab) Full text (opens in new tab) Psychedelics: classical psychedelics Hallucinogens Entheogens Psychotropics +9

Difficulties interpreting concentrations in fatal cases: example of 2,5-dimethoxy-4-chloroamphetamine.

Forensic Toxicology July 1, 2022 Benedicte Lelievre, Vincent Dupont, Celine Buchaillet et al.

Death related to the use of drugs is evident when drugs are detected in biological matrices within toxic levels, but sometimes it can be less obvious. Intoxications after 2,5-dimethoxy-4-chloroamphetamine (DOC) use are occurring but up to date, only one fatality has been reported. Here we present the case of a young woman admitted to hospital as she presented vomiting, convulsions and...

DOI: 10.1007/s11419-022-00628-8 (opens in new tab) Full text (opens in new tab) 2,5-dimethoxy-4-chloroamphetamine Fatal New psychoactive substances

Who uses digital drugs? An international survey of 'binaural beat' consumers.

Drug and Alcohol Review July 1, 2022 Monica J Barratt, Alexia Maddox, Naomi Smith et al. 19 citations

Digital drugs, or binaural beats claimed to elicit specific cognitive or emotional states, are a phenomenon about which little is known. In this brief report, we describe demographic and drug use correlates of binaural beat use, patterns of use, reasons for use and methods of access. The Global Drug Survey 2021 was translated into 11 languages; 30 896 responses were gathered from 22 countries....

DOI: 10.1111/dar.13464 (opens in new tab) Full text (opens in new tab) Cross-sectional study Hallucinogen Illicit drug Music +1

Classic and non‐classic psychedelics for substance use disorder: A review of their historic, past and current research

Addiction Neuroscience June 22, 2022 Fúlvio Rieli Mendes, Cristiane Dos Santos Costa, Victor Distefano Wiltenburg et al. 55 citations

Substance use disorder (SUD) is a global public health concern that affects millions of people worldwide. Considering current research, addiction has been noted as the last stage of a chronic disease that may impair brain reward circuit responses and affects personal and social life. Treatments for SUD face challenges including availability and limited pharmacological response, often resulting...

0841 Case Report: Can LSD be Associated with Chronic Exploding Head Syndrome?

Sleep May 25, 2022 Feby Puravath Manikat, Clete A. Kushida

Abstract Introduction Exploding head syndrome is a rare phenomenon characterized by a loud imagined noise at sleep onset. Less commonly, it is associated with a simultaneous stab of pain in the forehead. It may result in recurring arousals and anxiety regarding the events. The underlying pathophysiology remains unknown. Report of Cases: A 27 year old male with no past medical history presented...

Views on Using Psychoactive Substances to Self-Manage Functional Neurological Disorder: Online Patient Survey Results

The Journal of Neuropsychiatry and Clinical Neurosciences May 17, 2022 Matthew Butler, Mathieu Seynaeve, Abigail Bradley‐Westguard et al. 6 citations

Objective: Functional neurological disorder (FND) causes a high burden of disability and distress. Although it is a common disorder, there is a pressing need for improved access to evidence-based treatments. With difficulties in finding effective treatment, some people with FND may seek alternative means of symptom relief, such as legal and illicit psychoactive substances, although the...

Metabolites of Synthetic Cannabinoid 5F-MDMB-PINACA Retain Affinity, Act as High Efficacy Agonists and Exhibit Atypical Pharmacodynamic Properties at CB1 Receptors.

Toxicological sciences : an official journal of the Society of Toxicology April 26, 2022 Christian V Cabanlong, Lauren N Russell, William E Fantegrossi et al.

Synthetic cannabinoid receptor agonists (SCRAs) are a large group of abused psychoactive compounds that elicit numerous toxic effects not observed with cannabis, including death. Abuse of third-generation SCRA 5F-MDMB-PINACA (also known as 5F-ADB) has been associated with over 40 fatalities. This SCRA is metabolized to several active phase I metabolites, including excessively high post-mortem...

DOI: 10.1093/toxsci/kfac024 (opens in new tab) Full text (opens in new tab) G-protein coupled receptors Cb1 receptors Metabolites Novel psychoactive substances +2

Psychosocial and Drug Use Assessment of Regular vs. Non-Regular Ayahuasca Users in a Brazilian Sample: a Web-Based Survey

Substance Use & Misuse April 25, 2022 Dimitri Daldegan-Bueno, Dóra Révész, Paulo Rogério Morais et al. 15 citations

Background: Preliminary evidence suggests that long-term ayahuasca use is associated with better psychosocial outcomes and less drug use; however, available data on the association between ayahuasca intake frequency and psychosocial outcomes is limited. Objectives: We sought to characterize and investigate the association of regular ayahuasca use, as compared to non-regular use, on licit...